Ming He1, Zhen Chen1, Marcy Martin1, Jin Zhang1, Panjamaporn Sangwung1, Brian Woo1, Adriana H Tremoulet1, Chisato Shimizu1, Mukesh K Jain1, Jane C Burns2, John Y-J Shyy2. 1. From the Cardiovascular Research Center, Key Laboratory of Environment and Genes Related to Diseases (M.H., J.Z., J.Y.-J.S.), Department of Rheumatology, First Affiliated Hospital (M.H.), Xi'an Jiaotong University Health Science Center, China; Division of Cardiology, Department of Medicine (M.H., Z.C., M.M., B.W., J.Y.-J.S.) and Department of Pediatrics (A.H.T., C.S., J.C.B.), University of California, San Diego; Rady Children's Hospital, San Diego, CA (A.H.T., J.C.B.); Division of Biochemistry and Molecular Biology, University of California, Riverside (M.M.); and Case Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cardiovascular Research Center, Cleveland, OH (P.S., M.K.J.). 2. From the Cardiovascular Research Center, Key Laboratory of Environment and Genes Related to Diseases (M.H., J.Z., J.Y.-J.S.), Department of Rheumatology, First Affiliated Hospital (M.H.), Xi'an Jiaotong University Health Science Center, China; Division of Cardiology, Department of Medicine (M.H., Z.C., M.M., B.W., J.Y.-J.S.) and Department of Pediatrics (A.H.T., C.S., J.C.B.), University of California, San Diego; Rady Children's Hospital, San Diego, CA (A.H.T., J.C.B.); Division of Biochemistry and Molecular Biology, University of California, Riverside (M.M.); and Case Cardiovascular Research Institute, School of Medicine, Case Western Reserve University, Cardiovascular Research Center, Cleveland, OH (P.S., M.K.J.). jshyy@ucsd.edu jcburns@ucsd.edu.
Abstract
RATIONALE: Endothelial-mesenchymal transition (EndoMT) is implicated in myofibroblast-like cell-mediated damage to the coronary arterial wall in acute Kawasaki disease (KD) patients, as evidenced by positive staining for connective tissue growth factor (CTGF) and EndoMT markers in KD autopsy tissues. However, little is known about the molecular basis of EndoMT involved in KD. OBJECTIVE: We investigated the microRNA (miRNA) regulation of CTGF and the consequent EndoMT in KD pathogenesis. As well, the modulation of this process by statin therapy was studied. METHODS AND RESULTS: Sera from healthy children and KD subjects were incubated with human umbilical vein endothelial cells. Cardiovascular disease-related miRNAs, CTGF, and EndoMT markers were quantified using reverse transcriptase quantitative polymerase chain reaction, ELISA, and Western blotting. Compared with healthy controls, human umbilical vein endothelial cell incubated with sera from acute KD patients had decreased miR-483, increased CTGF, and increased EndoMT markers. Bioinformatics analysis followed by functional validation demonstrated that Krüppel-like factor 4 (KLF4) transactivates miR-483, which in turn targets the 3' untranslated region of CTGF mRNA. Overexpression of KLF4 or pre-miR-483 suppressed, whereas knockdown of KLF4 or anti-miR-483 enhanced, CTGF expression in endothelial cells in vitro and in vivo. Furthermore, atorvastatin, currently being tested in a phase I/IIa clinical trial in KD children, induced KLF4-miR-483, which suppressed CTGF and EndoMT in endothelial cells. CONCLUSIONS: KD sera suppress the KLF4-miR-483 axis in endothelial cells, leading to increased expression of CTGF and induction of EndoMT. This detrimental process in the endothelium may contribute to coronary artery abnormalities in KD patients. Statin therapy may benefit acute KD patients, in part, through the restoration of KLF4-miR-483 expression. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01431105.
RCT Entities:
RATIONALE: Endothelial-mesenchymal transition (EndoMT) is implicated in myofibroblast-like cell-mediated damage to the coronary arterial wall in acute Kawasaki disease (KD) patients, as evidenced by positive staining for connective tissue growth factor (CTGF) and EndoMT markers in KD autopsy tissues. However, little is known about the molecular basis of EndoMT involved in KD. OBJECTIVE: We investigated the microRNA (miRNA) regulation of CTGF and the consequent EndoMT in KD pathogenesis. As well, the modulation of this process by statin therapy was studied. METHODS AND RESULTS: Sera from healthy children and KD subjects were incubated with human umbilical vein endothelial cells. Cardiovascular disease-related miRNAs, CTGF, and EndoMT markers were quantified using reverse transcriptase quantitative polymerase chain reaction, ELISA, and Western blotting. Compared with healthy controls, human umbilical vein endothelial cell incubated with sera from acute KD patients had decreased miR-483, increased CTGF, and increased EndoMT markers. Bioinformatics analysis followed by functional validation demonstrated that Krüppel-like factor 4 (KLF4) transactivates miR-483, which in turn targets the 3' untranslated region of CTGF mRNA. Overexpression of KLF4 or pre-miR-483 suppressed, whereas knockdown of KLF4 or anti-miR-483 enhanced, CTGF expression in endothelial cells in vitro and in vivo. Furthermore, atorvastatin, currently being tested in a phase I/IIa clinical trial in KD children, induced KLF4-miR-483, which suppressed CTGF and EndoMT in endothelial cells. CONCLUSIONS: KD sera suppress the KLF4-miR-483 axis in endothelial cells, leading to increased expression of CTGF and induction of EndoMT. This detrimental process in the endothelium may contribute to coronary artery abnormalities in KD patients. Statin therapy may benefit acute KD patients, in part, through the restoration of KLF4-miR-483 expression. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01431105.
Authors: T Christen; V Verin; M Bochaton-Piallat; Y Popowski; F Ramaekers; P Debruyne; E Camenzind; G van Eys; G Gabbiani Journal: Circulation Date: 2001-02-13 Impact factor: 29.690
Authors: Adriana H Tremoulet; Sonia Jain; Preeti Jaggi; Susan Jimenez-Fernandez; Joan M Pancheri; Xiaoying Sun; John T Kanegaye; John P Kovalchin; Beth F Printz; Octavio Ramilo; Jane C Burns Journal: Lancet Date: 2014-02-24 Impact factor: 79.321
Authors: Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns Journal: J Pediatr Date: 2019-09-24 Impact factor: 4.406
Authors: Nassim E Ajami; Shakti Gupta; Mano R Maurya; Phu Nguyen; Julie Yi-Shuan Li; John Y-J Shyy; Zhen Chen; Shu Chien; Shankar Subramaniam Journal: Proc Natl Acad Sci U S A Date: 2017-09-26 Impact factor: 11.205